Sanofi’s Oral Treatment For Sleeping Sickness Gets FDA Approval
The FDA has approved Sanofi SA’s (NASDAQ:SNY) fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense…
Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India
Sanofi SA (NASDAQ:SNY) and GlaxoSmithKline Plc (NYSE:GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial…
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients…
Moderna’s COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ:MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine.…
Sanofi Invests To Build Internal Capabilities in mRNA
Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines.
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 28)
Sanofi Divests 16 Consumer Health Brands To Stada
Amid a reorganization scheme aimed at slashing costs and prioritizing blockbuster immunology Dupixent, Sanofi SA (NASDAQ:SNY) will offload 16 consumer health…
Sanofi’s Soliqua Shows Improved Blood Sugar Control Without Weigh Gain Against Premixed Insulin
Sanofi SA (NASDAQ:SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary…
AstraZeneca’s Nirsevimab Shows Favorable Safety, Tolerability Profile In Infants At High Risk Of RSV
AstraZeneca Plc (NASDAQ: AZN) announced data from the MEDLEY Phase 2/3 trial evaluating nirsevimab in infants at high risk of respiratory syncytial virus (RSV).